Abstract IL-i-induced osteoblast IL-6 production represents one possible mechanism by which IL-1 augments bone resorption. In this report, we show that the murine osteoblastic cell line (MC3T3-E1) expresses type 1 IL-1 receptors based on 1251. HrILla binding, blocked by type 1 IL-1R antibodies (35F5), and analysis of MC3T3 RNA by reverse transcription (RT)-DNA amplification and Northern analysis. MC3T3 cells do not express detectable type 2 IL-1R mRNA by RT-DNA amplification. IL-1 induces (IL-i ED50, 0.1 pM) IL-6 production through the type 1 IL-1R as 35F5 antibodies block IL-i-stimulated IL-6 production. Vitamin D3 increases IL-1R expression dose-and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-i's capacity to stimulate IL-6 production at low IL-1 levels. Both IL-1 and 1,25-(OH)2D3 induce type 1 IL-1R and not type 2 IL-1R upregulation based on ligand binding and RT-DNA amplification. Increased IL-1R expression requires a 5-7-h treatment and is protein/RNA synthesis dependent. These observations imply that IL-i-induced IL-6 production in osteoblasts is mediated by type 1 IL-iRs and that increased IL-1R expression could play a role in mediating IL-i-induced skeletal responses. (J.
Introduction
Osteoblasts are ideally positioned to function as cellular mediatprs of hormonally regulated skeletal metabolism (1) , and increasing evidence suggests that IL-I effects on the skeleton, including osteoclast activation, are mediated through the osteoblast. IL-i a and -f,, two of the most potent bone-resorbing factors on a molar basis (2) , are cytokines produced primarily, but not solely, by cells of the monocyte-macrophage lineage. Initiated with Gowen's report describing the capacity for IL-1 (or an IL-1-like factor) to stimulate bone resorption in organ cultures, experimental results continue to suggest that IL-I may serve as an important regulator ofbone remodeling (2) (3) (4) . Furthermore, IL-iIp is now considered to be the principal component of osteoclast activating factor: a mixture of factors de-rived from activation of heterogeneous leukocyte cultures that stimulates bone resorption in organ cultures (5) . The physiologic relevance of these in vitro observations has been underscored by the capacity for IL-1 to induce hypercalcemia associated with histologic evidence ofincreased osteoclastic activity in in vivo studies on rodents (6, 7) .
In vitro studies using transformed osteoblastic cell lines, primary osteoblast cultures, and nontransformed osteoblast cell lines have documented the capacity for IL-I to influence a number of osteoblastic matrix-related activities, including cellular proliferation, collagen and osteocalcin synthesis, alkaline phosphatase production, collagenase, and plasminogen activator production (8) (9) (10) (11) (12) (13) (14) . Additionally, osteoblasts are also stimulated by many bone-resorbing substances to secrete cytokines and other factors that can act locally in an autocrine and/or paracrine manner. One such factor is IL-6, which has been shown to influence osteoclast development in vitro (15) and stimulates bone resorption both in vitro ( 16) and induces hypercalcemia in vivo ( 17) . This cytokine is produced in abundance by osteoblasts after their exposure to IL-1 ( 16) and is present in elevated amounts in Paget's disease of bone ( 18) , a condition characterized by lytic bone lesions having increased numbers of osteoclasts.
While IL-1-stimulated IL-6 likely plays a role in IL-I-induced bone resorption, aspects of its induction by IL-1 remain undefined. For instance, the cellular effects of IL-1 are mediated by specific high-affinity IL-1 cell surface receptors (IL-1 R) ( 19) , ofwhich there are two types. Sequences for these two different cell surface IL-1 binding molecules predict membrane receptors with external domains that are characteristic of the immunoglobulin superfamily (20, 21 ) . It was originally thought that the type 1 IL-1R was expressed primarily on T cells, fibroblasts, and epithelial cells, whereas IL-1 binding by B cells, macrophages, or bone marrow cells was mediated by type 2 IL-lR(s) (22, 23) . However, recent data suggest that the segregated distribution of these receptor subtypes to different cell lineages may not be so straightforward (21 ) . In osteoblastic cells, 125I-IL- 1 ligand binding studies on a number ofosteoblast cell lines and osteoblast primary cultures have documented the presence of high-affinity IL-1 binding sites (24) (25) (26) (27) ; however, it remains unclear which IL-1 R(s) is expressed by osteoblasts.
Furthermore, the IL-I R that, when ligand bound, initiates the signal eventuating in IL-6 release is not known.
To address these issues, we have investigated aspects ofIL-6 production and IL-1 R expression and regulation utilizing MC3T3 cells. This cell line, established from calvaria of newborn C57B1/6 mice, is nontransformed and expresses an osteoblastic phenotype (28) . As Cells. The MC3T3-E1 (MC3T3) cell line was kindly provided by Dr. H. Tanaka (Okayama University, Okayama, Japan). The cells were maintained in a humidified atmosphere at 37°C in 5% CO2 in air. For cell passage (every 5-7 d), the confluent cell layers were treated with TE-PBS and, after rinsing, seeded at 2 X 104 cell/ ml in T75 tissue culture flasks ( 15 ml total volume). To ensure that the cells used in our experiments expressed an osteoblastic phenotype, PTH induction of cAMP, monolayer staining for alkaline phosphase activity, and culture morphology were assessed (data not shown). Based on changes in cell layer morphology from a "cobblestone" to a spindled appearance, together with a reduction ofalkaline phosphatase activity with increasing '25I-HrIL-Ja binding. HrIL-la was labeled with '25I (Na'25I,ICN) using enzymobeads (29) (Bio-Rad Laboratories, Richmond, CA) and the biochemical and biological activity of the preparation verified as described (30) . The then ligated overnight (140C) with T4 DNA ligase. Aliquots of these reactions were used to transform the DH5a strain (Max Effic a; BRL, Gaithersburg, MD) of E. coli that were streaked on LB agar supplemented with 50 ,g/ml ampicillin, 0.5 mM IPTG, and 40 jg/ml XGal. Selected colonies were cultured in ampicillin (50 ,g/ml) containing LB media. The insert sequences of both plasmids were verified utilizing primers complementary to the SP6 and T7 RNA polymerase initiation sites, alkali-denatured, miniprep-plasmid DNA, 35Sa-dATP (1250 Ci/mmol, DuPont-NEN, Wilmington, DE), Sequenase (USBiochemical Corp., Cleveland, OH) in a dideoxy chain termination method according to the manufacturer's instructions.
Type I and type 2 IL-JR mRNA assays. To detect the presence of MC3T3 type 1 and type 2 IL-IR mRNA, both reverse transcription/ DNA amplification (32) and Northern blot analysis were used. MC3T3 and CBA/CaJ splenocyte total cellular RNA were prepared by the method ofChirgwin et al. (33) , quantified by absorbance spectroscopy (1 A260 = 40 jg/ml), and analyzed on a 1% Seakem agarose (FMC, Rockland, ME)/formaldehyde (0.23%) gel (34) in Northern buffer to assure RNA integrity. Aliquots ofthis RNA were then used in reverse transcription/DNA amplification studies using the types 1 and 2 IL-lR primers. Portions of the amplified DNA were restriction digested with Saul or Pvull (Boehringer Mannheim Biochemicals) according to the manufacturer's instructions.
For Northern blots, MC3T3 and/or EL4 6.1 (gift of David Chaplin, Washington University, St. Louis, MO) total cell RNA were electrophoresed in 1% agarose gels as described above. The RNA was electroblotted onto Zeta probe nylon membranes according to manufacturer's instructions (Biorad Laboratories). The blots were prehybridized in cocktail containing 50% formamide, 0.25 M NaHPO4 (pH 7.2), 0.25 M NaCl, 1 mM EDTA, and 2% SDS for 1-2 h at 42°C. The type 1 murine IL-IR and IL-6 probes were generated by labeling the gel-purified DNA amplification product of plasmids P4ZIL-lRI .5 or P4ZIL-6 with [32P]adCTP (3,000 Ci/mmol, ICN Biomedicals Inc., Irvine, CA) by random priming (random primed DNA labeling kit, Boehringer Mannheim Biochemicals). The probe specific activity was estimated at 10'-10' cpm/,jg DNA. Hybridization (16-20 h, 42°C) was performed using 106 cpm/ml probe in the same buffer used for prehybridization. The membranes were then washed three times in 2X SSC, 0.1 % SDS at room temperature and then once in 0.2x SSC, 0.1 % SDS at 56°C for 1 h. For autoradiography, the blots were exposed to Kodak XAR film at -80°C for 1 wk.
IL-6 bioassay. Various dilutions ( 1:1-1:100,000) of MC3T3-conditioned media (in 100 jl) were prepared in 96-well microtiter plates using a5-MEM as the background media. B9 cells, 3-4 d after last passage, were rinsed once in serum and growth factor-free B9 media, suspended at 1 X 105 cells/ml in the same medium supplemented with 5% HIFCS, and then added ( 100-jil aliquots) to the previously prepared wells. The cultures were incubated for a 72-h period. To assess cell growth, the MTT dye conversion assay (35) was used. The data are reported in units (U), with one unit defined as the activity resulting in half-maximal response based on optical density. The standard deviation was < 15% of the mean. HrIL-la had no effects on B9 cellular proliferation at any concentration tested (0.01-1,000 pM, data not shown).
Results
In the first series of experiments, MC3T3 IL-I Rs were characterized by a number of methods, including '25I-HrIL-la cellsurface binding, antibody-blocking experiments, and mRNA analysis. As shown in Fig. 1 The next experiments determined the type of IL-I R(s) expressed by this osteoblast cell line. In the first experiment, 125I-HrIL-la binding studies were performed using either unlabeled HrIL-la or 35F5 (23) as competitors for '251-HrIL-I a binding. As shown in Fig. 2 A, both HrIL-la (20 nM) and 35F5 (1:100, 16 ,ug/ml) were equally effective at blocking 125i-HrIL-I a binding, suggesting that the majority ofthe osteoblastexpressed IL-I Rs were either immunologically closely related or identical to the type 1 IL-I R. Using 25-bp oligomer primers bracketing a 458-bp type 1 IL-IR sequence (20) , the presence of type 1 IL-I R mRNA molecules was assessed using a reverse transcriptase-DNA amplification protocol (32) . As the ethidium bromide-stained gel demonstrates (Fig. 2 B) , the DNA amplified from MC3T3 total RNA electrophoresed as a single band migrating at a point near the predicted product size (458 bp). Further confirmation that this DNA band had resulted from amplification of type I IL-I R mRNA was obtained from the capacity ofthe restriction enzyme SauI (heptameric restriction site) to completely cleave the amplified DNA into two fragments virtually the size predicted (Table I) by the restriction map of the cDNA corresponding to the amplified region. To verify that the amplified material was not the result of amplification of contaminating DNA, parallel reactions were performed that either lacked reverse transcriptase (Fig. 2 B, (Fig. 2 C) , the probe hybridized to a band just above the 28S RNA in a position identical to that observed in EL4 6.1 RNA (20) . To exclude the presence of type 2 IL-R mRNA, reverse transcribed MC3T3 total cell RNA was amplified using either type 1 or type 2 IL-I R primers. As a control, splenocyte total cell RNA was used. As shown in Fig. 3 To determine the relationship between the HrIL-1 a concentrations that stimulate IL-6 production and the IL-l R Kd, as well as to determine whether the type 1 IL-I R was mediating this IL-1 effect, MC3T3 cells were exposed to various HrIL-I a levels in the presence and absence of 35F5. As Fig. 4 (Fig. 4 B) . At 100 pM HrIL-lIa, the amount of cytokine present was sufficient to overcome the level of receptor blockade due to 35F5 and no inhibition of IL-6 production was observed. An equivalent amount of rat IgG had no impact on IL-1-induced IL-6 production. To confirm that the secreted activity was IL-6, the supernatants ( 1:100) from IL-1-stimulated MC3T3 cells pretreated with media, rat IgG (5 Ag/ml), or 35F5 (5 ,ug/ml) were exposed to anti-IL-6 antibodies before their combination with B9 cells. As Fig. 4 (38, 39) , we have observed that low levels of IL-1 enhanced IL-1 R expression in a T cell line (40) . To assess this possibility in MC3T3, cultures were treated with a range of IL-1 concentrations (0.1-1,000 pM HrIL-la) for 24 h followed by '25I-HrIL-lIa binding. As shown in Fig. 5 
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To address the functional consequence of 1,25-(OH)2D3-induced IL-1 R upregulation on IL-6 production, MC3T3 cells were treated with 1,25-(OH)2D3 for 24 h to upregulate IL-IR expression, followed by exposure to low concentrations of HrIL-Ia. As shown in Fig. 7 A, 1,25-(OH)2D3 pretreatment leads to enhanced secretion of IL-1-induced (125, 250 and 1,000 fM HrIL-1 a) IL-6 bioactivity into MC3T3-conditioned media. To examine whether steady-state levels of IL-6 mRNA were also positively impacted, total cell RNA was collected from MC3T3 cells pretreated with 1,25-(OH)2D3 or media alone (24 h) followed by their exposure to 1 pM HrIL-1 a for 3 h. Northern blots were prepared and probed with a 32P-labeled IL-6 DNA probe. As the autoradiogram shows (Fig. 7 B) , neither control (lane a) nor (Fig. 8 B) , the effect of 1 pM HrIL-la on MC3T3 '25I-HrIL- formed to define the kinetics of IL-IR upregulation. As Fig. 10 shows, the IL-I upregulating effect induced by either HrIL-1 a (1 pM) or 1,25-(OH)2D3 (5 nM) was not detectable until after 5-7 h of incubation. By 24 h of incubation with either substance, significant differences in IL-I R expression between the groups became apparent. Also, consistent with other experiments where MC3T3 cells were treated with either 1 pM HrILlCa or 5 nM 1,25-(OH)2D3 (data not shown), HrIL-lIa treated MC3T3 cells exhibited a greater increase in '25I-HrIL-l a binding than cells treated with l,25-(OH)2D3. Ui. . Vitamin D3 pretreatment augments HrIL-la-induced MC3T3 IL-6 production. (A) MC3T3 bioassayable IL-6 production. MC3T3 cells were treated for 24 h with media alone or with media containing 5 nM l,25-(OH)2D3 to upregulate IL-lR levels. The media was then removed and media alone or media containing various amounts of HrIL-I a was added for an additional 24 h. The supernatants were collected for use in the B9 assay for IL-6 using the MTT dye conversion assay. The data are expressed as in Fig. 4 A. (B) MC3T3 IL-6 mRNA expression. Confluent dishes of MC3T3 cells were treated with media alone or media with 5 nM 1,25-(OH)2D3 as in A. The media were then removed and replaced with media alone or media containing 1 pM HrIL-la. Total cell RNA was harvested 1 10 100 1,000 10,000 after a 3-h HrIL-la exposure and 5 gg electrophoresed, blotted, and probed with a 32P-labeled murine IL-6 cDNA probe as described.
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The lanes are as follows: a, control pretreated (CPTX); b, 1,25- (Table II) . However, in the presence of either CHX or ACT D, IL-I R upregulation induced by either HrIL-la or 1,25-(OH)2D3 was abolished. Cell viability was unaffected by the 24-h inhibitor treatment as > 95% ofthe cells excluded trypan blue after toxin exposure. Furthermore, the removal of CHX or ACT D from MC3T3 cells followed by the readdition of 1,25-(OH)2D3 or HrIL-lIa for an additional 24 h revealed that MC3T3 cells could recover and subsequently express increased IL-1 Rs (see Recovery, Table II ).
Discussion
In this study, we have shown that MC3T3 cells express a large number (3,000-10,000 receptors/cell) of high-affinity (Kd 100 pM) IL-lRs (Fig. ) . Based on the capacity for an antimurine type 1 IL-1R monoclonal antibody (35F5) to block virtually all of the specific 1251I-HrIL-lca binding (Fig. 2 A) , together with the presence of type 1 IL-1 R mRNA (Fig. 2 , B and C) and absence of type 2 IL-I R mRNA (Fig. 3) , we conclude that all of the 1251I-HrIL-la binding on resting MC3T3 cells was due to cell surface type 1 IL-1 Rs. MC3T3 cells increased IL-6 production in response to HrIL-I a levels well below (0.1 pM) the IL-I R Kd (Fig. 4) . The HrIL-I a sensitivity of MC3T3 IL-6 production typifies certain IL-1 induced responses observed in other cells. Using an IL-lresponsive T cell line (MD10 cells) derived in our laboratory, we have previously reported that IL-1-driven proliferation occurs at HrIL-Ia levels far below the MDO0 IL-IR Kd (40) . These observations parallel the results reported for IL-1-stimulated IL-2 production by a murine T lymphoma cell line (36) . On the other hand, not all IL-1-driven responses occur at such low ligand concentrations. In MDO0 cells, the induction of intracellular alkalinization by HrIL-1 a requires cytokine levels in the range of the IL-1 R Kd (40) . Further, IL-1 stimulated fibroblast proliferation, which is apparently mediated indirectly through PDGF AA induction (41) , also occurs in response to IL-1 levels in the range of the IL-I R Kd (36) . Hence, IL-1 signaling pathways may be ligand-concentration dependent.
Because IL-1-induced MC3T3 IL-6 production (Fig. 4) and MDIO proliferation (37) had a similar IL-1 concentration dependence, we reasoned that IL-1 per se could increase the level of its expression on MC3T3 cells similar to its effects on the IL-1R expressed by MDO0 cells (40) . In MDO0 cells, HrIL-1 a exerts a biphasic effect on its own receptor expression; low concentrations (< 1.0 pM) either upregulate or do not affect IL-1R levels, while higher concentrations (> 10 pM), approaching the IL-1 R K, downregulate IL-IR expression (40) . Using HrIL-1 a over a wide concentration range failed to diminish MC3T3 IL-IR levels, including 1 nM HrIL-1 a, an amount 1 log order greater than the MC3T3 IL-1 R Kd ( (38, 42) . These data suggest that the regulation of IL-I R expression in osteoblastic cells may fundamentally differ from fibroblast IL-1 R regulation, although both cells are derived from connective tissue.
Using primary osteoblast-enriched cultures from neonatal murine calvaria, Shen et al. (26) recently described a high number of IL-1 Rs that appear to be modulated in a manner different from those expressed by MC3T3 cells. In the presence of 2 ng/ml (-100 pM) HrIL-lIa, IL-1R levels appeared to be diminished after a 24-h treatment (26) . Two major differences between their studies and those reported here may explain the discordance between our respective findings. One possibility is that the observed differences reflect unique qualities expressed B Figure 9 . Both (Fig.  8), dose (Fig. 6) , and metabolite-specific (Fig. 6) (OH )2D3 mediates its effects on ILporal burst of IL-I secretion by secreting increased amounts of IL-6. While it is unclear which cell in the bone microenvironment could provide IL-I, osteoclasts, mononuclear preosteoclasts, or other mononuclear phagocytes are likely candidates because they are members of the monocyte-macrophage family (46) (47) (48) . Evidence that local IL-I production occurs in nor-O__ _ _ mal animals comes from in situ hybridization studies using probes for IL-I a and # in bone tissue from normal mice (49) .
In these studies, cells located near the bone surface exhibited a positive hybridization signal for IL-la, implying that synthesis of IL-I mRNA occurs normally in the skeleton and suggesting that IL-1 could play a physiologic role in skeletal metabolism. 12 18 24 IL-l 's potential role in the pathogenesis ofskeletal disease is underscored by the observation that circulating leukocytes (hours) from certain subgroups ofpatients with high-turnover osteopo-,-Ia upregulating effect on the rosis spontaneously secrete large amounts of IL-1 (50 Fig. 5 but without acid periarticular bone resorption as well as generalized osteoporoe mean (n = 2) and range of sis (51, 52) . While it is unknown if these phenomena are Is.
causally linked to the osteoporotic condition, in light of the findings reported here it is possible that low but increased levels of IL-1 in vivo may serve to systemically prime the osteoblastic -1 R levels through the nubone-lining cell population to respond in an exaggerated manclear vitamin L3 receptor ( 44) .
To confirm that IL-I R upregulation impacted IL-I cellular responsiveness, IL-6 production was examined in cells that had been pretreated with 1,25-(OH)2D3 to upregulate IL-IRs (Fig.  7) . In the presence oflow IL-I concentrations, 1,25-(OH)2D3-pretreated MC3T3 cells exhibited enhanced IL-6 production. The effect of 1,25-(OH)2D3 on MC3T3 cells is similar to the effects of IL-4 on T cells where IL-4 increases IL-1 R levels and also acts synergistically with low concentrations ofIL-I to stimulate cellular proliferation (40) . This may be due to a "left shift" in the IL-I dose-response curve because increased receptor levels, like greater ligand concentrations, may result in more signal-generating receptor-ligand complexes. These results add biologic support to the observations of Curtis et al. (45 ) , who observed that IL-1-induced effects occurred at lower IL-I levels in Chinese hamster ovary cells engineered to express high levels of the type 1 IL-i R than in control cells that expressed < 100 type 1 IL-i Rs per cell.
The mechanism involved in both the HrIL-la and 1,25-(OH)2D3 IL-i R upregulation involves new protein and RNA synthesis based on inhibitor studies using CHX and ACT D (Table II) . Using monoclonal antibodies directed against the murine type 1 IL-IR (23) , all of the increases in MC3T3 12511 HrIL-Ia binding induced by either HrIL-la or 1,25-(OH)2D3 can be attributed to elevated type 1 IL-I R expression (Fig. 9) . Furthermore, RT-DNA amplification of RNA obtained from IL-i-or 1,25-(OH)2D3-treated MC3T3 cells failed to reveal induction oftype 2 IL-i R mRNA, indicating that only the type 1 IL-I R is expressed in these conditions.
The capacity for HrIL-la and 1,25-(OH)2D3 to both increase bone resorption in vitro and in vivo as well as augment MC3T3 IL-I R expression suggests that osteoblastic IL-I R regulation may be an important step in bone remodeling. If local IL-I production characterized certain phases of the resorptive process, then factors that enhance IL-i R expression could serve to "prime" osteoblasts to respond to a subsequent tem- Table H ner to transient or sustained increases in locally or systemically produced IL-I. In any event, these studies suggest that osteoblast type 1 IL-1 receptor regulation may represent a key determinant of osteoblast IL-I responsiveness and therefore mediate the magnitude of IL-I's skeletal effects.
